Evolva Holding (EVE) AI Stock Analysis

• Market Cap: CHF6.56M
• Dividend Yield: N/A
• Average Volume (3M): 6.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: -100.00%
• EPS Growth: 97.27%
• Country: CH
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 7,230,626
• 10 Day Avg. Volume: 6,146
• 30 Day Avg. Volume: 6,263
• PEG Ratio: -0.06
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 2.5
• Revenue Forecast (FY): CHF60.90M

• Rating: 42 Neutral
• Price Target: CHF0.83 ▲(0.73% Upside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is held down primarily by weak financial performance (zero 2024 revenue and ongoing negative free cash flow), despite the benefit of a debt-free balance sheet and improved 2024 profitability. Technicals remain bearish with the stock trading below major moving averages, while valuation is difficult to support due to a negative P/E and no dividend yield data.

Positive Factors

Debt-free balance sheet

A zero-debt capital structure materially lowers bankruptcy and interest-rate risk, preserving strategic optionality. Over 2–6 months this supports funding flexibility for R&D, licensing or pivot initiatives without immediate refinancing pressure, improving resilience.

Improved 2024 profitability

Recording positive EBIT and net income in 2024 indicates management can cut costs or realign operations to profitability. If sustained alongside a revived revenue base, this structural improvement increases the likelihood of self-funded operations and stronger partner outcomes.

Lean operating footprint

A small workforce implies a lower fixed-cost base, which durablely reduces cash burn while the business repositions. Over months this makes runway extension via cost control more feasible and enables nimble redeployment of resources toward higher-return projects or partnerships.

Negative Factors

Revenue fell to zero in 2024

A complete loss of reported revenue is a structural business-model failure: without sustainable sales or recurring income, profitability and cash metrics are fragile. Over 2–6 months, absent new commercial traction this undermines credibility with partners and access to non-dilutive funding.

Negative free cash flow trend

Persistent negative operating and free cash flow indicates structural cash burn despite accounting profits in 2024. Over the medium term this forces reliance on external financing or asset sales, constraining strategic investments and increasing dilution or refinancing risk.

Compressed equity and asset base

Shrinking assets and equity materially reduce balance-sheet firepower for R&D, licensing, or commercialization. Over several months this lowers collateral for lenders, limits ability to absorb shocks, and narrows strategic options like partnerships or acquisitions that require capital backing.

Evolva Holding Business Overview & Revenue Model

Company Description

Evolva Holding (EVE) is a Swiss-based biotechnology company focused on the research, development, and commercialization of innovative ingredients derived from nature. The company leverages advanced biosynthesis technology to produce high-value compounds for use in various sectors, including food, cosmetics, and personal care. Evolva's core products are sustainable and environmentally friendly alternatives to traditional ingredients, offering enhanced performance and value.

How the Company Makes Money

Evolva makes money primarily through the sale of its biosynthesized ingredients to businesses in the food, beverage, flavor, fragrance, and personal care industries. The company operates on a B2B model, partnering with major companies to incorporate its ingredients into their products. Revenue streams include direct sales of ingredients, licensing agreements, and long-term partnerships with key industry players. Evolva benefits from its proprietary biotechnology platform, which allows for efficient, scalable production of high-quality, sustainable compounds. Additionally, the company may earn income through research and development collaborations and grants, contributing to its overall revenue.

Evolva Holding Financial Statement Overview

Summary

Financial statements indicate major operating weakness: revenue fell to zero in 2024 and free cash flow remains negative, signaling continued cash burn and mixed earnings quality. Offsetting positives include zero debt and improved profitability in 2024, but sustainability is uncertain without a revenue base.

Income Statement

Results show a sharp reset in the business model: 2024 annual revenue fell to zero (down 100% vs. 2023), after already declining in 2023. Profitability improved materially in 2024 with positive EBIT and net income, but with no revenue base and margins reported at 0%, the quality and repeatability of earnings look less proven. Prior years (2019–2023) were consistently loss-making with deeply negative profit margins, highlighting a long history of weak operating economics despite periods of revenue growth earlier in the cycle.

Balance Sheet

Leverage looks conservative with total debt at zero in 2023–2024 and a low debt load historically, which reduces solvency risk. However, the equity base and asset base have compressed dramatically versus earlier years (large step-down by 2022–2024), signaling balance sheet shrinkage and reduced financial flexibility. Returns on equity swung from extremely negative in 2023 to positive in 2024, but the volatility underscores an unstable earnings profile.

Cash Flow

Cash generation remains a key weakness: operating cash flow and free cash flow are negative across all periods provided, including 2024, indicating ongoing cash burn. While cash burn improved significantly in 2024 versus 2023, the longer-term trend still reflects structurally negative free cash flow and high variability year to year. With free cash flow negative despite positive 2024 net income, earnings quality appears mixed and cash conversion remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	9.44M	15.54M	9.88M	7.54M
Gross Profit	0.00	0.00	-4.83M	-8.89M	-9.31M	-2.24M
EBITDA	3.70M	3.70M	-98.36M	-34.52M	-31.82M	-20.60M
Net Income	-851.20K	1.04M	-105.23M	-43.37M	-41.27M	-29.87M
Balance Sheet
Total Assets	7.08M	7.54M	9.83M	131.01M	156.17M	166.89M
Cash, Cash Equivalents and Short-Term Investments	6.31M	6.75M	5.84M	5.14M	11.00M	19.67M
Total Debt	0.00	0.00	0.00	15.06M	10.84M	9.02M
Total Liabilities	849.50K	945.30K	4.28M	24.77M	24.40M	21.80M
Stockholders Equity	6.24M	6.60M	5.55M	106.24M	131.77M	145.09M
Cash Flow
Free Cash Flow	-1.03M	-2.44M	-9.72M	-21.13M	-33.57M	-28.97M
Operating Cash Flow	-1.03M	-2.44M	-9.25M	-18.88M	-29.79M	-23.36M
Investing Cash Flow	3.52M	3.52M	15.95M	-1.76M	-4.64M	-5.60M
Financing Cash Flow	-3.33M	-163.10K	-5.97M	14.77M	25.72M	8.86M

Evolva Holding Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Positive. The current price of 0.82 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.83, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.13 is Neutral, neither overbought nor oversold. The STOCH value of 61.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:EVE.

Evolva Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	67 Neutral	CHF372.27M	15.53	―	―	744.64%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	48 Neutral	CHF159.08M	-2.43	-49.86%	―	-100.00%	14.45%
SANN	48 Neutral	CHF226.37M	-3.17	-301.13%	―	-56.85%	-186.55%
EVE	42 Neutral	CHF6.56M	-9.90	-9.73%	―	-100.00%	97.27%